{"id":1598,"date":"2023-02-13T23:00:00","date_gmt":"2023-02-13T22:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/"},"modified":"2023-05-23T14:11:17","modified_gmt":"2023-05-23T14:11:17","slug":"cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/","title":{"rendered":"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9"},"content":{"rendered":"<p align=\"justify\"><strong>PARIS, <\/strong><strong>France <\/strong>Ipsen (Euronext\u00a0: IPN\u00a0; ADR\u00a0: IPSEY) annonce aujourd\u2019hui les r\u00e9sultats sur trois\u00a0ans minimum \u2013 avec un suivi m\u00e9dian de 44\u00a0mois \u2013 de l\u2019essai de Phase\u00a0III CheckMate\u00a0-9ER. Les donn\u00e9es recueillies dans le cadre de l\u2019\u00e9tude d\u00e9montrent que Cabometyx<sup>\u00ae<\/sup> (cabozantinib) en association avec le nivolumab am\u00e9liore le taux de survie et le taux de r\u00e9ponse apr\u00e8s trois\u00a0ans dans le traitement en premi\u00e8re ligne de l\u2019aRCC, par rapport au sunitinib.<sup>1<\/sup> Ces r\u00e9sultats seront pr\u00e9sent\u00e9s \u00e0 l\u2019occasion de l\u2019ASCO\u00a0GU qui se tiendra du 16 au 18\u00a0f\u00e9vrier\u00a02023.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-1598","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9 - Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9 - Annual Report\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/\" \/>\n<meta property=\"og:site_name\" content=\"Annual Report\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T14:11:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/\",\"name\":\"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9 - Annual Report\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\"},\"datePublished\":\"2023-02-13T22:00:00+00:00\",\"dateModified\":\"2023-05-23T14:11:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"name\":\"Annual Report\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\",\"name\":\"Annual Report\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Annual Report\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9 - Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/","og_locale":"fr_FR","og_type":"article","og_title":"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9 - Annual Report","og_url":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/","og_site_name":"Annual Report","article_modified_time":"2023-05-23T14:11:17+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/","url":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/","name":"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9 - Annual Report","isPartOf":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#website"},"datePublished":"2023-02-13T22:00:00+00:00","dateModified":"2023-05-23T14:11:17+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/annualreport\/fr\/"},{"@type":"ListItem","position":2,"name":"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/annualreport\/#website","url":"https:\/\/www.ipsen.com\/annualreport\/","name":"Annual Report","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/annualreport\/#organization","name":"Annual Report","url":"https:\/\/www.ipsen.com\/annualreport\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"Annual Report"},"image":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/"}}]}},"parsely":{"version":"1.1.0","canonical_url":"https:\/\/ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Cabometyx\u00ae en association avec le nivolumab d\u00e9montre des b\u00e9n\u00e9fices en termes de survie d\u2019apr\u00e8s les donn\u00e9es recueillies sur trois ans pour le traitement en premi\u00e8re ligne du cancer du rein avanc\u00e9","url":"http:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/","mainEntityOfPage":{"@type":"WebPage","@id":"http:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\/"},"thumbnailUrl":"","image":{"@type":"ImageObject","url":""},"articleSection":"Non classifi\u00e9(e)","author":[{"@type":"Person","name":"IPSEN"}],"creator":["IPSEN"],"publisher":{"@type":"Organization","name":"Annual Report","logo":""},"keywords":[],"dateCreated":"2023-02-13T22:00:00Z","datePublished":"2023-02-13T22:00:00Z","dateModified":"2023-05-23T14:11:17Z"},"rendered":"<script type=\"application\/ld+json\" class=\"wp-parsely-metadata\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"Cabometyx\\u00ae en association avec le nivolumab d\\u00e9montre des b\\u00e9n\\u00e9fices en termes de survie d\\u2019apr\\u00e8s les donn\\u00e9es recueillies sur trois ans pour le traitement en premi\\u00e8re ligne du cancer du rein avanc\\u00e9\",\"url\":\"http:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\\\/\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/cabometyx-en-association-avec-le-nivolumab-demontre-des-benefices-en-termes-de-survie-dapres-les-donnees-recueillies-sur-trois-ans-pour-le-traitement-en-premiere-ligne-du-cancer-du-rein\\\/\"},\"thumbnailUrl\":\"\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"\"},\"articleSection\":\"Non classifi\\u00e9(e)\",\"author\":[{\"@type\":\"Person\",\"name\":\"IPSEN\"}],\"creator\":[\"IPSEN\"],\"publisher\":{\"@type\":\"Organization\",\"name\":\"Annual Report\",\"logo\":\"\"},\"keywords\":[],\"dateCreated\":\"2023-02-13T22:00:00Z\",\"datePublished\":\"2023-02-13T22:00:00Z\",\"dateModified\":\"2023-05-23T14:11:17Z\"}<\/script>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/ipsen.com\/p.js"},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release\/1598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release\/1598\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/media?parent=1598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/categories?post=1598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/tags?post=1598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}